Annual Information Form Fiscal Year Ended April 30, 2020 September 11, 2020 Table of Contents Advisories ................................................................................................................................................................................... 4 Forward-Looking Information .................................................................................................................................................... 4 Corporate Structure ................................................................................................................................................................... 6 Name and Incorporation ............................................................................................................................................................................ 6 Inter-Corporate Relationships .................................................................................................................................................................... 6 Description of Business............................................................................................................................................................. 6 The Drug Development Process ................................................................................................................................................................ 6 Resverlogix Current Development Stage: Phase 3 BETonMACE Complete ............................................................................................ 7 Apabetalone (RVX-208).............................................................................................................................................................................. 8 Epigenetic Mechanism of Action: Single Therapeutic Target with Multiple Biological Effects ............................................................... 8 BET Inhibition Targets Pathways and Markers That Are Linked to CVD .................................................................................................. 9 Resverlogix’s Drug Development Strategy and Commercial Rationale ................................................................................................ 10 Cardiovascular Disease and Diabetes Mellitus ..................................................................................................................................... 11 Chronic Kidney Disease and End-Stage Renal Disease ........................................................................................................................ 12 Neurodegenerative Disease ................................................................................................................................................................... 12 Competitive Environment ....................................................................................................................................................................... 13 Key Products in Development (Resverlogix and Competitors).............................................................................................................. 16 General Development of the Business ................................................................................................................................... 17 History of Apabetalone Clinical Development ........................................................................................................................................ 17 Recent Clinical Developments ................................................................................................................................................................ 18 Recent Scientific Developments ............................................................................................................................................................ 21 Potential Orphan Disease and Additional Indications ........................................................................................................................... 23 Completed, Current and Planned Apabetalone (RVX-208) Clinical Trials ............................................................................................ 25 Regulatory Affairs .................................................................................................................................................................................... 25 Intellectual Property ................................................................................................................................................................................ 25 Clinical and Scientific Advisory Boards .................................................................................................................................................. 26 Financing ................................................................................................................................................................................................. 28 Licensing .................................................................................................................................................................................................. 30 Recent Developments ............................................................................................................................................................................. 31 Risk Factors ............................................................................................................................................................................. 31 Risks Relating to Our Business .............................................................................................................................................................. 31 Risks Relating to our Intellectual Property ............................................................................................................................................. 40 Risks Relating to Owning our Common Shares ..................................................................................................................................... 41 Dividends ................................................................................................................................................................................. 42 Description of Capital Structure.............................................................................................................................................. 42 Common Shares ...................................................................................................................................................................................... 42 Preferred Shares ..................................................................................................................................................................................... 42 Market for Securities ............................................................................................................................................................... 43 Directors and Executive Officers ............................................................................................................................................. 45 Name, Occupation and Security Holdings.............................................................................................................................................. 45 Audit Committee Matters ........................................................................................................................................................................ 47 2 Cease Trade Orders, Bankruptcies, Penalties or Sanctions ................................................................................................................. 48 Conflicts of Interest ................................................................................................................................................................................. 48 Interests of Management and Others in Material Transactions ........................................................................................... 48 Transfer Agent and Registrar .................................................................................................................................................. 49 Material Contracts ................................................................................................................................................................... 49 Interests of Experts .................................................................................................................................................................. 50 Additional Information ............................................................................................................................................................. 50 Schedule “A” – Audit and Finance Committee Charter ......................................................................................................... 51 Glossary .................................................................................................................................................................................... 57 References ............................................................................................................................................................................... 62 3 Advisories Conventions In this Annual Information